PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: ECON Corporate Services / InvestorIdeas.com™

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

InvestorIdeas.com Issues the Sector Close Up – Pharmaceutical and Biotech Stocks - InvestorIdeas.com, a leading online global investor resource, issues the Sector Close Up – Pharmaceutical and Biotech Stocks (OTCBB: BPMA)
InvestorIdeas.com Issues the Sector Close Up – Pharmaceutical and Biotech Stocks

 

NewswireToday - /newswire/ - Point Roberts, WA, United States, 2007/10/22 - InvestorIdeas.com, a leading online global investor resource, issues the Sector Close Up – Pharmaceutical and Biotech Stocks (OTCBB: BPMA).

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Brokerage/Trading Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

InvestorIdeas.com, a leading online global investor resource, issues the Sector Close Up – Pharmaceutical and Biotech Stocks. Gene therapy, which entails the introduction of genetic material into a person’s cells to fight or prevent disease, is a highly promising area but one that is long on theory and short on commercial product.

Benda Pharmaceutical, Inc. (OTCBB: BPMA) is a China-based pharmaceutical company that has become recognized for its cancer gene therapy treatment Gendicine®, which represents the world’s first gene therapy medicine on the market for the treatment of cancer. Gendicine® has been used to treat more than 50 types of malignant tumors across 6,000 patients, including more than 1,800 foreigners. According to the Company, in clinical trials on 135 patients affected by head and neck tumors, 64% had their tumors eliminated after one month of Gendicine® treatment - a 340% increase in efficacy relative to traditional treatments.

According to Justin Davis from After Market Support, LLC, North American representatives for Benda Pharmaceutical, “The addition of Gendicine® to Benda’s drug portfolio thrusts the Company to the leading edge of both the gene therapy revolution and the world’s ongoing fight against cancer. As the first cancer-treating gene therapy drug available to the public – anywhere - Gendicine® has garnered international attention and has turned both the medical and investing spotlights directly on Benda. Moreover, the demonstrated efficacy of Gendicine® has already translated into immediate financial returns for Benda - $3.8 MM in orders in one day after a recent medical conference in China. With the Company preparing to present the latest independent findings to an international gene therapy symposium in Europe, Benda finds itself at the cusp of what could become a global phenomenon.”

Another player in the gene therapy arena is Introgen Therapeutics, Inc. a biopharmaceutical company focused on targeted molecular therapies for the treatment of cancer and other diseases. Introgen’s gene therapy drug ADVEXIN® has not yet been approved – it is currently in Phase 3 clinical trials for the treatment of head and neck cancer and Li-Fraumeni Syndrome. According to the Company, regulatory filings in both the United States and in Europe are expected to be completed by the end of 2007.

Sector Close Up – Cancer Treatment Plays
Delcath Systems, Inc. developer of technology for targeted delivery of therapeutic and chemotherapeutic agents, recently announced that its Phase III trial was approved by the U.S. Food and Drug Administration under a Fast Track designation. Despite this progress, the Company has seen its shares drop more than a dollar since mid-September to its current level of $2.87.

Cell Genesys, Inc. currently conducting Phase 3 trials of the Company’s GVAX™ immunotherapy for prostate cancer, has rebounded slightly since early August’s share price of $3.22, closing Friday at $3.41.

Benda Pharmaceutical, Inc. (OTCBB: BPMA), on forecasts for 2008 of over $20 million in revenue from the Company’s cancer treatment Gendicine®, has been trading between $2.20-$2.49 over the past few weeks, up from the $0.70 level at which it began trading under one year ago.

Introgen Therapeutics, Inc. has seen its share price move from $3.16 at the beginning of August, to its recent close of $4.02, an increase of approximately 27%.

At the beginning of 2006, pharmaceutical giant, Pfizer received FDA approval for Sutent® for the treatment of rare forms of intestinal and kidney cancers. Sutent® is currently in trials for the treatment of breast, lung, and colorectal cancer. Pfizer shares closed recently at $24.07.
Since mid-August, Bristol-Myers Squibb shares have risen approximately 5% and ImClone has seen dramatic results, up $13.48 in the same time period, based on Friday’s close. Both companies have recently found themselves in the spotlight after an announcement that an agreement has been formed with Merck KGaA to co-develop and co-market the cancer treatment Erbitux® in Japan.

Showcase Pharmaceutical Company:
Benda Pharmaceutical Inc. (OTCBB: BPMA), a China-based pharmaceutical company, is a pure play on explosive Chinese pharmaceutical spending and the global search for a cancer cure. Compensation is disclosed in disclaimer below.

About InvestorIdeas.com
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing covering over thirty industry sectors and global markets including China, India, Middle East and Australia. InvestorIdeas.com Disclaimer:. Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. Benda Pharmaceutical, Inc. (OTCBB: BPMA) pays $4000USD per month. Benda Pharmaceutical, Inc. is also a client of After Market Support, LLC.

Source: InvestorIdeas.com, Benda Pharmaceutical, Inc.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Brokerage/Trading Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: ECON Corporate Services / InvestorIdeas.com™

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 
 
  Your Banner Ad showing on ALL
Brokerage/Trading articles,
CATCH Visitors via Your Competitors Announcements!


InvestorIdeas.com Issues the Sector Close Up – Pharmaceutical and Biotech Stocks

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Dawn Van Zant 
800-665-0411 dvanzant[.]investorideas.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any ECON Corporate Services / InvestorIdeas.com™ securities in any jurisdiction including any other companies listed or named in this release.

Brokerage/Trading via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From ECON Corporate Services / InvestorIdeas.com™ / Company Profile


Read Brokerage/Trading Most Recent Related Newswires:

SRMEX's Vice Chairman Eikichi Hirano About the Gradual Expansion of Capital Market
Xtrade Wins Best Broker in the Middle East Award
Russian Foreign Trade Reports on Russian Trade with North American Countries Q1 2016
DarkMaindFX Introduces the Beta Version of its Economic Indicator Services
Hermes International Expo to Celebrate 25th Anniversary in Delaware County
GoldSilver Central Approved As Singapore Bullion Market Association Member
OANDA Acquires Tradestation Forex Accounts
[TYPO FOUND BY SYSTEM] Beeline Broking Ltd Launches 'Tailor Made Brokerage Plan'
Signals365.com Announces Key Features - Makes it the Best Binary Options Signals Service
Binary Options Signals from Signals365.com Helps Traders to Get Higher Win-Rate
/RC/ Van Ecker Couder Associates Announce Expansion Program
/RC/ Voth Nixon Group Bolsters Deferred Income Annuity
Grant Becker Associates Chalks Up Another Successful Year of CSR Activities
Evanson Asset Management Dividend Stocks to Safeguard An All-weather Portfolio
AKFinancials Announces its 2015 Forex Course Schedule

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  JobsWare.com

Visit  NAKIVO, Inc.





 
  ©2016 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)